Introducing GelCount™ 2
Improving on the industry benchmark
After extensive development, we’re thrilled to unveil the second generation of GelCount - the imaging device that’s setting the standard for cancer biologists around the globe.
For the past 15 years, GelCount has become the benchmark tool for accelerating the processing of in vitro colony, spheroid, and organoid assays, and now it has evolved; with a revised design, faster processing and a more intuitive user experience.
Introducing GelCount 2, Andy Obeid, CEO of Oxford Optronix commented:
“The colony formation assay is essential for understanding how cancer cells survive in response to treatments. With over 250 GelCount systems already empowering researchers worldwide and more than 500 scientific citations to its name, GelCount has played a crucial role in the quest for effective cancer therapies. Now, with GelCount 2, we’re not just continuing this legacy; we’re elevating it.”
Featuring a redesigned hardware system and an innovative version 2 software platform, GelCount 2 brings you:
- 30-50% faster imaging for quicker results.
- A streamlined user experience with our latest software.
- Upcoming support for Ibidi® 15-well 3D chamber slides
- Upcoming AI-powered detection capabilities for colony, spheroid, and organoid cultures.
GelCount 2 shipments begin in December 2024.Join us in revolutionizing cancer research.
Bookmark our news feed or follow us on X to keep abreast of Oxford Optronix news and updates.
